Keona Pang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Keona Pang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Guillaume Paré
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
2 shared publications - Alice Man
Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton Health Sciences (E.S., K.P., P.B.M., A.M., J.G., Y.L., P.B., G.L.D.R., M.K., M.P., G.P.), McMaster University, Hamilton, Ontario, Canada
1 shared publication - Catherine Pauline M. Hayward
Department of Pathology and Molecular Medicine McMaster University Hamilton Ontario Canada
1 shared publication - Elad Shemesh
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
1 shared publication - Guilherme Luiz da Rocha
Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton Health Sciences (E.S., K.P., P.B.M., A.M., J.G., Y.L., P.B., G.L.D.R., M.K., M.P., G.P.), McMaster University, Hamilton, Ontario, Canada
1 shared publication - Josef Graf
Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton Health Sciences (E.S., K.P., P.B.M., A.M., J.G., Y.L., P.B., G.L.D.R., M.K., M.P., G.P.), McMaster University, Hamilton, Ontario, Canada
1 shared publication
Latest Publications
- 5 November 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
Genetic-Phenotypic Discordance Reveals Distinct Cardiovascular and Mortality Risk at HDL Cholesterol Extremes
BACKGROUND: Risk at high-density lipoprotein cholesterol (HDL-C) extremes may reflect genetic predisposition, ancestry, or region, but their relative contributions remain unknown. We characterized extreme HDL-C associations with atherosclerotic cardiovascular disease and mortality, and examined whether genetic-phenotypic discordance identifies risk beyond measured HDL-C. METHODS: Atherosclerotic cardiovascular disease–free participants from UKB (UK Biobank) and All of Us (AoU) with extremely low (2.3 mmol/L; based on standard clinical guidelines) HDL-C were analyzed. A 247-variant polygenic score stratified European ancestry participants at each HDL-C extreme into tertiles; discordant groups had measured HDL-C contradicting genetic predisposition. RESULTS: Among 408 353 UKB and 115 423 AoU participants, extremely low HDL-C was associated with higher atherosclerotic cardiovascular disease (UKB: hazard ratio [HR], 1.33 [95% CI, 1.27–1.39]; AoU: HR, 1.32 [95% CI, 1.08–1.61]) and mortality (UKB: HR, 1.25 [95% CI, 1.20–1.30]; AoU: HR, 1.64 [95% CI, 1.37–1.96]) across ancestries. Extremely high HDL-C was associated with excess mortality in UKB European ancestry (HR, 1.28 [95% CI, 1.19–1.38]), driven by COPD (HR, 2.64 [1.94–3.59]) and lung infections (HR, 2.24 [95% CI, 1.48–3.39]), but not in AoU European ancestry. In UKB, this was confined to genetically discordant high HDL (high-density lipoprotein; polygenic score HDL T1; HR, 1.53 [95% CI, 1.22–1.92]); genetically concordant high HDL showed progressively lower mortality. Genetically discordant low HDL (polygenic score HDL T3) carried higher atherosclerotic cardiovascular disease (UKB: HR, 1.20 [95% CI, 1.08–1.34]; AoU: HR, 1.44 [95% CI, 1.15–1.81]) and mortality (UKB: HR, 1.22 [95% CI, 1.11–1.34]; AoU: HR, 1.75 [95% CI, 1.21–2.54]) than concordant low HDL (polygenic score HDL T1), comparable in magnitude to a 10 mm Hg increment in systolic blood pressure. CONCLUSIONS: Extreme HDL-C levels carry different cardiovascular and mortality risk depending on whether they reflect or contradict genetic predisposition, with additional variation by ancestry and region.
- 5 November 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
Genetic-Phenotypic Discordance Reveals Distinct Cardiovascular and Mortality Risk at HDL Cholesterol Extremes
BACKGROUND: Risk at high-density lipoprotein cholesterol (HDL-C) extremes may reflect genetic predisposition, ancestry, or region, but their relative contributions remain unknown. We characterized extreme HDL-C associations with atherosclerotic cardiovascular disease and mortality, and examined whether genetic-phenotypic discordance identifies risk beyond measured HDL-C. METHODS: Atherosclerotic cardiovascular disease–free participants from UKB (UK Biobank) and All of Us (AoU) with extremely low (2.3 mmol/L; based on standard clinical guidelines) HDL-C were analyzed. A 247-variant polygenic score stratified European ancestry participants at each HDL-C extreme into tertiles; discordant groups had measured HDL-C contradicting genetic predisposition. RESULTS: Among 408 353 UKB and 115 423 AoU participants, extremely low HDL-C was associated with higher atherosclerotic cardiovascular disease (UKB: hazard ratio [HR], 1.33 [95% CI, 1.27–1.39]; AoU: HR, 1.32 [95% CI, 1.08–1.61]) and mortality (UKB: HR, 1.25 [95% CI, 1.20–1.30]; AoU: HR, 1.64 [95% CI, 1.37–1.96]) across ancestries. Extremely high HDL-C was associated with excess mortality in UKB European ancestry (HR, 1.28 [95% CI, 1.19–1.38]), driven by COPD (HR, 2.64 [1.94–3.59]) and lung infections (HR, 2.24 [95% CI, 1.48–3.39]), but not in AoU European ancestry. In UKB, this was confined to genetically discordant high HDL (high-density lipoprotein; polygenic score HDL T1; HR, 1.53 [95% CI, 1.22–1.92]); genetically concordant high HDL showed progressively lower mortality. Genetically discordant low HDL (polygenic score HDL T3) carried higher atherosclerotic cardiovascular disease (UKB: HR, 1.20 [95% CI, 1.08–1.34]; AoU: HR, 1.44 [95% CI, 1.15–1.81]) and mortality (UKB: HR, 1.22 [95% CI, 1.11–1.34]; AoU: HR, 1.75 [95% CI, 1.21–2.54]) than concordant low HDL (polygenic score HDL T1), comparable in magnitude to a 10 mm Hg increment in systolic blood pressure. CONCLUSIONS: Extreme HDL-C levels carry different cardiovascular and mortality risk depending on whether they reflect or contradict genetic predisposition, with additional variation by ancestry and region.
- Open Access
- 11 September 2026
- Published by Wiley in International Journal of Laboratory Hematology
Is It Time to Raise the Threshold for Critically Low Fibrinogen? Insights From a Retrospective, Consecutive‐Case Cohort Study of Low Fibrinogen due to Various Causes
Introduction: Fibrinogen deficiency is an important coagulation abnormality, with diverse causes. Methods: A consecutive‐case cohort study of adult and pediatric patients with low Clauss fibrinogen at four acute care hospitals was undertaken to explore findings, causes, and predictors of outcomes, including the optimal fibrinogen critical value to predict all‐cause mortality. Results: Over 11 months, 4.9% of tested patients (349/7183, after excluding n = 4 for preanalytical errors) had fibrinogen deficiency (63.6% male; 86.8% adult; 29.2% with liver disease; 14.0% with massive transfusion; 19.5% with fibrinogen < 1.0 g/L, the historical critical value; none with a diagnosed inherited deficiency). Primary causes of fibrinogen deficiency were: cardiovascular surgery (CVS); trauma; overt, not overt and potential/not scorable (no D‐dimer results) disseminated intravascular coagulation (DIC); liver disease; acute bleeding; and other (including uncertain) causes. After Bonferroni correction, overt and potential/not scorable DIC were associated with significantly lower fibrinogen levels and higher mortality than most other causes were, particularly compared to trauma ( p < 0.0001). Median time to death after diagnosing fibrinogen deficiency was 1 (IQR: < 1–7) day. A Clauss fibrinogen ≤ 1.3 g/L had optimal sensitivity and specificity for predicting mortality among fibrinogen‐deficient patients, and multivariate analyses indicated it was a strong, independent predictor of death (adjusted odds ratio [95% confidence intervals]: 6.2 [2.9–13.6] vs. ≤ 3.6 for liver disease and DIC). Spearman correlation indicated that the nadir Clauss fibrinogen level had a negative correlation ( r = −0.34, p < 0.0001) to the amount of fibrinogen replacement received. Conclusions: Low Clauss fibrinogen was commonly acquired and levels ≤ 1.3 g/L were optimal for predicting all‐cause mortality.
- 11 September 2026
- Published by Wiley in International Journal of Laboratory Hematology
Open AccessIs It Time to Raise the Threshold for Critically Low Fibrinogen? Insights From a Retrospective, Consecutive‐Case Cohort Study of Low Fibrinogen due to Various Causes
Introduction: Fibrinogen deficiency is an important coagulation abnormality, with diverse causes. Methods: A consecutive‐case cohort study of adult and pediatric patients with low Clauss fibrinogen at four acute care hospitals was undertaken to explore findings, causes, and predictors of outcomes, including the optimal fibrinogen critical value to predict all‐cause mortality. Results: Over 11 months, 4.9% of tested patients (349/7183, after excluding n = 4 for preanalytical errors) had fibrinogen deficiency (63.6% male; 86.8% adult; 29.2% with liver disease; 14.0% with massive transfusion; 19.5% with fibrinogen < 1.0 g/L, the historical critical value; none with a diagnosed inherited deficiency). Primary causes of fibrinogen deficiency were: cardiovascular surgery (CVS); trauma; overt, not overt and potential/not scorable (no D‐dimer results) disseminated intravascular coagulation (DIC); liver disease; acute bleeding; and other (including uncertain) causes. After Bonferroni correction, overt and potential/not scorable DIC were associated with significantly lower fibrinogen levels and higher mortality than most other causes were, particularly compared to trauma ( p < 0.0001). Median time to death after diagnosing fibrinogen deficiency was 1 (IQR: < 1–7) day. A Clauss fibrinogen ≤ 1.3 g/L had optimal sensitivity and specificity for predicting mortality among fibrinogen‐deficient patients, and multivariate analyses indicated it was a strong, independent predictor of death (adjusted odds ratio [95% confidence intervals]: 6.2 [2.9–13.6] vs. ≤ 3.6 for liver disease and DIC). Spearman correlation indicated that the nadir Clauss fibrinogen level had a negative correlation ( r = −0.34, p < 0.0001) to the amount of fibrinogen replacement received. Conclusions: Low Clauss fibrinogen was commonly acquired and levels ≤ 1.3 g/L were optimal for predicting all‐cause mortality.